Crossmark

Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified

Published Online: 2025-11-28

Published Print: 2026-03

Authors

Li, Xiangyu

Yuan, Lingjing

Li, Jiandi
License Information

Text and Data Mining valid from 2025-11-28

Version of Record valid from 2025-11-28
More Information

Article History

Received: 17 September 2025

Accepted: 12 November 2025

First Online: 28 November 2025

Declarations

:

: This study does not require ethical approval and consent to participate to use the publicly available and anonymized datasets from the FAERS.

: The authors declare no competing interests.

Document is current